Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Soy protein supplement may prevent or delay the development of prostate cancer in patients who have elevated prostate-specific antigen (PSA) levels. PURPOSE: Randomized phase II trial to determine the effectiveness of soy protein supplement in preventing prostate cancer in patients who have elevated PSA levels.

Key facts

Study ID

NCT00031746

Run by

Alliance for Clinical Trials in Oncology

People needed

26

Starts

2000-02-01

Expected to finish

2006-06-01

Last updated by the study team

2016-07-19

Who can join

Age: 50 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Walter Reed Army Medical Center — Washington D.C., District of Columbia, United States
• CCOP - Hematology-Oncology Associates of Central New York — Syracuse, New York, United States
• Community General Hospital of Greater Syracuse — Syracuse, New York, United States
• Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
• Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.